A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
Post Marketing Surveillance (PMS) Study for Cibinqo Tablet (Abrocitinib) in Patients With Moderate to Severe Atopic Dermatitis (AD) in Korea
Sponsor: Pfizer
A observational or N/A phase clinical study on Dermatitis, Atopic, this trial is actively recruiting participants. The trial is conducted by Pfizer and has accumulated 18 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
18 versions recorded-
Jan 2026 — Present [monthly]
Recruiting
-
Dec 2025 — Jan 2026 [monthly]
Recruiting
-
Oct 2025 — Dec 2025 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Recruiting
▶ Show 13 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Recruiting
-
Jun 2025 — Jul 2025 [monthly]
Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
Aug 2023 — Jul 2024 [monthly]
Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Recruiting
-
Feb 2023 — Jul 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Not Yet Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Not Yet Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Not Yet Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .